User profiles for B Shea

Beverley Shea

- Verified email at uottawa.ca - Cited by 82984

Brian F Shea, Pharm.D.

- Verified email at koniag-gs.com - Cited by 12323

[HTML][HTML] Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

BJ Shea, JM Grimshaw, GA Wells, M Boers… - BMC medical research …, 2007 - Springer
Background Our objective was to develop an instrument to assess the methodological
quality of systematic reviews, building upon previous tools, empirical evidence and expert …

[HTML][HTML] ROBIS: a new tool to assess risk of bias in systematic reviews was developed

…, JPT Higgins, DM Caldwell, BC Reeves, B Shea… - Journal of clinical …, 2016 - Elsevier
Objective To develop ROBIS, a new tool for assessing the risk of bias in systematic reviews (rather
than in primary studies). Study Design and Setting We used four-stage approach to …

Glucosamine therapy for treating osteoarthritis

…, L Maxwell, TP Anastassiades, B Shea… - Cochrane database …, 2005 - cochranelibrary.com
Background Osteoarthritis (OA) is a common form of arthritis and is often associated with
significant disability and impaired quality of life. This is an update of a Cochrane review first …

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

…, L Sandhu, PL Santaguida, HJ Schünemann, B Shea… - bmj, 2016 - bmj.com
… Criteria for reaching risk of bias judgements for the seven domains are provided in supplementary
tables B and C. If none of the answers to the signalling questions for a domain …

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses

GA Wells, B Shea, D O'Connell, J Peterson, V Welch… - 2000 - scholar.archive.org
b) study controls for any additional factor (This criteria could be modified to indicate specific
control for a second important factor.) ♦ … Selection of the non exposed cohort a) drawn from …

Incidence of adverse drug events and potential adverse drug events: implications for prevention

…, SD Small, D Servi, G Laffel, BJ Sweitzer, BF Shea… - Jama, 1995 - jamanetwork.com
Objectives. —To assess incidence and preventability of adverse drug events (ADEs) and
potential ADEs. To analyze preventable events to develop prevention strategies. Design. —…

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

BJ Shea, BC Reeves, G Wells, M Thuku, C Hamel… - bmj, 2017 - bmj.com
The number of published systematic reviews of studies of healthcare interventions has
increased rapidly and these are used extensively for clinical and policy decisions. Systematic …

Systems analysis of adverse drug events

…, R Nemeskal, LA Petersen, K Porter, D Servi, BF Shea… - Jama, 1995 - jamanetwork.com
Objective. —To identify and evaluate the systems failures that underlie errors causing
adverse drug events (ADEs) and potential ADEs. Design. —Systems analysis of events from a …

Effect of computerized physician order entry and a team intervention on prevention of serious medication errors

…, JM Teich, E Burdick, M Hickey, S Kleefield, B Shea… - Jama, 1998 - jamanetwork.com
Context.—Adverse drug events (ADEs) are a significant and costly cause of injury during
hospitalization.Objectives.—To evaluate the efficacy of 2 interventions for preventing …

AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews

BJ Shea, C Hamel, GA Wells, LM Bouter… - Journal of clinical …, 2009 - Elsevier
OBJECTIVE: Our purpose was to measure the agreement, reliability, construct validity, and
feasibility of a measurement tool to assess systematic reviews (AMSTAR). STUDY DESIGN …